Disc Medicine’s (IRON) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $70.00 price objective on the stock. Other research analysts have also recently issued research reports about the stock. Stifel Nicolaus boosted their price objective on […]

Leave a Reply

Your email address will not be published.

Previous post Kinsale Capital Group (NYSE:KNSL) Coverage Initiated at Oppenheimer
Next post Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded by Argus to “Buy”